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Abstract Indazolium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1019) and its Na+ 
analogue (KP1339) are two of the most prominent non-platinum antitumor metal complexes currently 
undergoing clinical trials. After intravenous administration, they are known to bind to human serum 
albumin (HSA) in a non-covalent manner. In order to elucidate their HSA binding sites, displacement 
reactions with the established site markers warfarin and dansylglycine as well as bilirubin were 
monitored by spectrofluorimetry, ultrafiltration−UV-vis spectrophotometry and/or capillary zone 
electrophoresis. Conditional stability constants for the binding of KP1019 and KP1339 to sites I and II 
of HSA were determined, indicating that both Ru(III) compounds bind into both sites with moderately 
to strong affinity (logK1’ = 5.3-5.8). No preference for either binding site was found and similar results 
were obtained for both metal complexes, demonstrating low influence of the counter ion on the 
binding event.  
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Abbreviations 
EM  emission wavelength 
EX  excitation wavelength 
BGE  background electrolyte 
BR  bilirubin 
CE  capillary electrophoresis 
CZE  capillary zone electrophoresis 
DG  dansylglycine 
HMM  high molecular mass 
HSA  human serum albumin 
KP1019 indazolium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] 
KP1339 sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] 
LMM  low molecular mass 
NAMI-A imidazolium trans-[tetrachlorido(dimethylsulfoxide)(1H-imidazole)ruthenate(III)] 
Tf  transferrin 
WF  warfarin 
  molar absorptivity 
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Introduction 
 
The field of the metal-based anticancer drugs was initiated by cisplatin, one of the leading 
agents in the clinical use [1]. Ruthenium compounds are currently considered the most likely 
candidates for the next generation of metal-based anticancer drugs [2,3]. Two representatives 
of this class of compounds have entered clinical trials so far: imidazolium trans-
[tetrachlorido(dimethylsulfoxide)(1H-imidazole)ruthenate(III)] (NAMI-A) [4,5] and 
indazolium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1019) [6–8] (see Chart 1 
for structures). Only very moderate toxicities were observed in the case of KP1019 [6,7,9] 
whereas NAMI-A treatment was accompanied by painful blister formation at higher dosage, 
however that is actually higher than the advised dosage  [10]. 
Chart 1 
KP1019 shows remarkable antineoplastic activity against a wide number of preclinical tumor 
models, including cisplatin resistant colorectal tumors and some primary explanted human 
tumors [2,6,11,12]. Although the pharmacological target for antitumor ruthenium compounds 
has not been unequivocally identified, it is unlikely that their modes of action are similar to 
that of cisplatin [7]. The limitation in the application of KP1019 in the clinics was the low 
solubility and therefore, the maximum tolerated dose was not reachable in clinical trials [8]. 
According to the clinical study the maximum plasma level was about 0.3 mM for KP1019 [8]. 
This problem was solved by the replacement of the indazolium counter ion by sodium 
(KP1339, Chart 1). KP1339 has a significantly better water solubility compared to KP1019 
and participates in an ongoing clinical trial.  
The minor side effects of the Ru(III) compounds may be related to their mode of 
action. After intravenous administration the complex binds to highly abundant serum proteins 
such as human serum albumin (HSA) and transferrin (Tf) [13–15]. The selective tumor 
targeting can be realized by the enhanced permeability and retention effect of the tumor 
tissue, and by the overexpression of transferrin receptors on cancer cells [16]. A further 
reason for their selectivity is the insufficient formation of new blood vessels in rapidly 
growing tumors that results in a more reductive environment as compared to normal tissue 
and facilitates Ru(III) reduction to Ru(II) (“activation by reduction” hypothesis) [17–19] and 
therefore ligand exchange and coordination towards biological targets such as DNA or 
proteins [7,12,20]. 
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Therefore, reactions of anticancer metallodrugs with proteins are of considerable 
interest as these interactions might feature processes that are crucial for the biodistribution, 
the toxicity and even the mechanism of action of this important group of anticancer agents. 
KP1019 is known to bind to a large degree to HSA, which is suggested to act as a ruthenium 
reservoir [15,21,22]. HSA is the most abundant of the blood serum proteins occurring to the 
extent of 0.63 mM. It contributes to colloid osmotic pressure and is chiefly responsible for the 
maintenance of blood pH. The protein serves as a transport vehicle for a wide variety of 
ligands, including fatty acids, bilirubin, steroids, metal ions, and various pharmaceuticals. It 
comprises a single chain with 585 amino acids organized in three similar domains (I, II, and 
III), each consisting of two subdomains (IA, IB, etc.). The principal regions of ligand binding 
sites of albumin are located in hydrophobic cavities in subdomains IIA and IIIA (sites I and 
II) [23–25]. A typical site marker for site I is the anticoagulant drug warfarin (WF) [26–29], 
while dansylglycine (DG) shows specificity for site II (see Fig. S1) [30–32]. Initial rapid 
binding of KP1019 takes place in a non-covalent manner at the hydrophobic binding sites of 
HSA, however after a longer incubation time the type of the interaction is converted slowly to 
a protein-coordinated form [33]. Similar behavior of NAMI-A and its pyridine analogues was 
found recently based on mainly electron paramagnetic resonance spectroscopic measurements 
[34,35]. A binding ratio of four KP1019 complex anions on a single HSA molecule was 
determined by CD and confirmed by inductively coupled plasma atomic emission 
spectroscopic (ICP-AES) method [23]. More recently, the KP1019−HSA association 
constants were determined by means of capillary electrophoresis (CE) as 9.9 × 103 M-1, and 
by CE coupled to ICP-mass spectrometry (MS) as 1.06 × 104 M-1 [13,21]. It is noteworthy 
that separation methods such as CE may shift the chemical equilibrium of a reaction mixture 
and therefore spectroscopic methods provide a better means to investigate binding constants. 
Furthermore, the actual binding sites of KP1019 on HSA remain elusive. Herein we report on 
displacement experiments with well-established site markers for sites I and II and with the 
heme metabolite bilirubin (BR, Fig. S1), which is also transported by HSA and has relevance 
for patients with hyperbilirubinaemia [36], by means of spectroscopic and separation 
methods.  
 
Results and discussion 
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Ru(III) complexes are known to undergo hydrolysis in aqueous solution [37,38], with the 
kinetics being dependent on the pH and the chloride concentration in the incubation medium 
[37]. Human plasma has a pH of about 7.4 and the chloride concentration is 104 mM. In order 
to suppress the hydrolysis to a wide extent, a chloride concentration of 150 mM was chosen in 
our experiments and the incubations were done in 20 mM phosphate buffer (pH 7.40). This 
approach was successful for other anticancer agents like cisplatin and Ru(II)-arene complexes 
[39-42]. However, the chloride/water exchange in the KP1019 and KP1339 is not suppressed 
completely within a 1 h interval under this condition (25 °C, pH 7.40, 150 mM Cl−) (Fig. S2), 
and especially in the case of KP1019 a higher extent of aquation takes place (after 1 h ~ 9%). 
It is noteworthy that the recovery of the HSA from the human blood and its dissolution 
in water and use under aerobic condition can easily lead to the oxidation of the free thiol 
group of the cysteine-34 residue. Thus, HSA is most probably at least partially present in the 
dimeric form. The dimerization may alter the binding capacities [43] but as the level of 
dimerization is unknown, the average binding capacity of the monomeric and dimeric HSA 
were calculated.    
Initially, the conditional stability constants for the reaction of the Ru(III) complexes 
KP1019 and KP1339 to HSA were determined by means of fluorescence spectroscopy. HSA 
contains a single tryptophan (Trp214) residue that is responsible for the majority of the 
intrinsic fluorescence of the protein. Upon excitation at 295 nm, HSA emits strong 
fluorescence at 350 nm which can be attenuated by a binding event at or close to the Trp214 
due to its susceptibility to changes in its environment. Addition of KP1339 to HSA quenches 
its fluorescence very efficiently (Fig. 1), indicating that the conformation of the hydrophobic 
binding pocket in site I is significantly affected by the Ru(III) complex binding. Because self-
absorption of these complexes is significant at the wavelength range of the quenching 
measurements and would interfere with modeling (Table 1), a correction equation was applied 
to minimize this effect (see section Materials and methods/Spectrofluorimetric 
measurements). Trynda-Lemiesz and coworkers also observed the quenching of the emission 
of Trp by KP1019 [22], however under the conditions applied, the samples show high 
absorbance and no binding data was reported. The conditional stability constants calculated 
using the Stern-Volmer approach for KP1339 at a chosen λEM (inset of Fig. 1.b) and with 
PSEQUAD [44] for both complexes using the whole spectra were found to be similar (Table 
1). Graphical solutions such as the Stern-Volmer plot, which is widely used in the literature 
[45,46], cannot be applied in the emission wavelength range if the ligand has a significant 
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intrinsic emission, such as the indazolium counter cation in KP1019 at EX = 295 nm (see 
Figs. S3 and S4; KP1339 is not fluorescent). Experiments to elucidate the role of the 
indazolium ion in the binding of KP1019 and HSA, revealed only weak binding of indazole to 
site II, and no binding to site I. Other critical point of the Stern-Volmer approach is that the 
substitution of the equilibrium concentrations by analytical concentrations in the formula may 
not provide trustable stability constants. The conditional binding constants logK’ under these 
conditions were computed from the quenching studies as 4.69(6) and 5.66(6) for KP1339 and 
KP1019, respectively. This big difference between the two binding constants has no 
reasonable chemical explanation, there are methodological uncertainties. In order to elucidate 
the problem the direct interaction between HSA and complexes KP1019 and KP1339 was also 
be followed by ultrafiltration quantification measurements with UV-vis spectrophotometric 
quantification. 
Fig. 1 
Table 1 
It is noteworthy that ultrafiltration might induce release of weakly surface bound ligands. In 
this setup, the non-bound fraction was separated from HSA and the [HSA‒Ru(III) complex] 
by ultrafiltration with a 10 kDa cut-off membrane filter resulting in low (LMM) and high 
molecular mass (HMM) fractions. The LMM samples were analyzed by UV-vis spectroscopy 
and compared to reference spectra (see Fig. S5 for the HSA−KP1339 system), yielding the 
ratios of the non-bound and total amount of the compounds. From these data pairs, the 
stoichiometry and conditional stability constants of the HSA complexes were calculated (Fig. 
2 and Table 1). This method allows the determination of stepwise stability constants, while 
spectrofluorimetry can only be used for the first step because of the highly diluted samples 
resulting in strong dissociation. Comparing the logK’1 values calculated by the different 
methods it can be seen that ultrafiltration–UV-vis gave somewhat lower values than 
spectrofluorimetry. The main reason is probably the different experimental conditions of the 
methods used:  interference in the equilibrium during the separation process in ultrafiltration 
and mM concentrations at spectrofluorimetry, and mM concentrations at ultrafiltration in the 
quantification process. 
Fig. 2 
In recent years, researchers have become interested in determining the binding sites of 
metallodrugs on biomolecules for improved design of next generation drug candidates. It is 
known that KP1019 binds to HSA initially in a non-covalent manner then the coordination of 
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histidine nitrogen(s) to the Ru(III) centre takes place [33]. The spectrofluorimetric quenching 
studies and the ultrafiltration (vide supra) cannot give information about the feature of the 
binding mode whether it is non-covalent or coordinative. In order to get a deeper insight into 
the binding event, a strategy involving particular site markers was applied to probe the nature 
of the preferred binding site, as well as the specificity and affinity towards the protein.  
Warfarin, bilirubin were used as site markers for site I, and dansylglycine for site II; 
and  Fig. 3 demonstrates that these compounds have a weak or negligible molar fluorescence 
emission at the given excitation wavelengths. The addition of HSA induced an increase in 
intensity due to the binding of these compounds to the respective site on the protein. Based on 
the molar fluorescence spectra, which are only valid under the conditions and instrument 
settings applied, stability constants were calculated using PSEQUAD [44]. The conditional 
HSA binding constants (logK’) for WF, BR and DG are comparable with data obtained by us 
and others [26-32,36,47,48] (Table S1) and are found to be practically temperature 
independent (25 °C vs. 37 °C) within the uncertainty of the measurement. The calculations for 
BR required application of a self-absorbance correction because of its considerable 
absorbance at the excitation wavelength. However, the Ru(III) complexes and their HSA 
adducts [HSA−Ru(III) complex] have no intrinsic emission in this wavelength range. 
Fig. 3 
The HSA−site marker adducts [HSA−WF], [HSA−BR] and [HSA−DG] emit 
intensively and their displacement by other ligands from the binding pocket of the protein is 
accompanied by a considerable decrease in the emission intensity. Therefore, the 
displacement of the site markers at various concentrations of the Ru(III) complexes could be 
followed via intensity changes of the emission spectra. In case of the HSA−WF−KP1339 
system, the initial intensity decreased by about 50% upon addition of an 8-fold excess of the 
Ru(III) complex (Fig. 4) accompanied by a bathochromic shift, which can be attributed to the 
increasing free WF fraction and its higher emission maximum. Similar results were obtained 
for the reaction of KP1019 and [HSA−WF] and the binding constants calculated from WF 
displacement and quenching measurements (Table 1) are in good agreement. 
Fig. 4 
The displacement reactions of BR and DG displayed a similar trend as found for WF 
(for DG see Fig. 5) and no significant difference for KP1019 and KP1339 was observed (for 
the conditional stability constants see Table 1). Based on these data it can be concluded that 
the nature of the counter ion does not affect the ability of the trans-[tetrachloridobis(1H-
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indazole)ruthenate(III)] anion to interact with HSA. However, in the case of KP1339 the 
constant derived from the quenching experiments is one order of magnitude lower than from 
WF displacement, whereas in case of KP1019 similar results were obtained. Although it can 
happen that a small portion of the KP1339 loses the axial indazole ligand and since the free 
ligand exhibit an extremely strong emission at 295 nm excitation wavelength, it can cause a 
lower quenching of the HSA fluorescence. It is noteworthy that the displacement of WF and 
BR by KP1019 was also observed previously; however no quantitative data evaluation was 
performed [22]. 
Fig. 5 
In addition to the spectroscopic studies, the reactions of [HSA–Ru(III) complex] with 
WF and DG were studied by capillary zone electrophoresis (CZE)−UV-vis and 
ultrafiltration−UV-vis methods (BR could not be studied because of its low aqueous solubility 
and extinction coefficient). CE has been used to determine chemical equilibria in protein–
metallodrug systems [49,50]. Compared with other separation-based assays such as high-
performance liquid chromatography (HPLC), CE possesses distinctive advantages such as 
shorter analysis time, use of electrolyte compositions compatible with physiological 
incubation conditions, and no stationary phase involved in separation [51]. A similar approach 
as in the spectroscopic studies was followed with the HSA-to-site marker ratio kept constant 
and the KP1019 and KP1339 content was varied. No interaction between the Ru(III) 
compounds and the site markers were detected by CZE under the applied conditions and a 
linear concentration-peak height correlation was observed for the metal complexes (Fig.s S6 
and S7). The data were analyzed based on the increase of the peak heights belonging to the 
released site markers as a result of their displacement by the Ru(III) complexes [48]. Fig. 6 
shows the displacement of WF by the Ru(III) complexes monitored by CZE. The increasing 
amount of the non-bound site marker with increasing metal complex concentration confirms 
that these complexes tend to compete for the HSA binding sites with WF; and the same 
tendency is observed in the case of DG. Moreover, an 8-fold excess of the complexes was 
sufficient to complete the displacement of the site markers at 1:1 site marker-to-HSA ratio. 
Again, very similar behavior for the two Ru(III) complexes has been observed with the 
ultrafiltration displacement approach. Analysis of the LMM fraction by spectrofluorimetry 
and UV-vis method revealed an increasing quantity of non-bound site marker with higher 
metal complex concentration (see Fig. S8). This indicates that both KP1339 and KP1019 are 
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able to compete with WF and DG for the respective HSA binding sites with similar binding 
strength and to a similar extent. 
Fig. 6 
An important feature for the clinical application of such drug compounds may be the 
fact that both Ru(III) complexes can displace BR from HSA (Fig. 7).  The unbound fraction 
of Ru(III) complex calculated on the basis of the stability constants (Table 1) is increased at 
higher concentrations of BR in a hypothetical system containing 630 mM HSA (according to 
its physiological serum concentration) and equimolar KP1339, i.e., an increase of the BR 
concentration from 11 up to 68 mM causes a significant 2.5-fold increase in the free, unbound 
fraction of the Ru(III) complexes (Fig. 8). It is noteworthy that all the BR is bound to HSA 
under this condition, and no BR displacement takes place by the Ru(III) complex. Generally 
the free portion of a drug can reach the final target, hence is responsible for the biological 
effect, while HSA has a temporarily reservoir role [52,53]. Taking into account that patients 
with liver malfunctions have higher bilirubin levels, this result may be of significance for their 
treatment with such Ru(III) complexes. 
Fig. 7 
Fig. 8 
 
Conclusions 
 
It is essential to explore the interactions of anticancer metallodrugs with serum proteins as 
these interactions might feature processes that are crucial for biodistribution, toxicity and even 
their mechanism of action. Human serum albumin is the most abundant plasma protein and 
responsible for the binding and transport of numerous molecules including metal complexes. 
The characterization of the binding of the Ru(III) complexes KP1339 and KP1019 to albumin 
and the determination of the preferred binding sites were performed as this protein is 
considered as their primary binding partner after intravenous administration.  
A panel of methods comprising spectrofluorimetry, CZE−UV-vis and ultrafiltration−UV-vis 
was used to investigate the interaction between HSA and KP1019 and KP1339. Using 
warfarin, bilirubin and dansylglycine as site markers, the preferred binding sites for these 
novel chemotherapeutics were determined by displacement experiments. Considerable 
displacement of all site markers takes place upon addition of both Ru(III) compounds 
demonstrating their ability to bind to both sites I and II of albumin. No significant differences 
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were found in the binding ability at these binding sites based on the spectrofluorimetric 
measurements; and both compounds KP1019 and KP1339 are able bind into both sites with 
moderately strong affinity. Therefore, the counter ion does not affect the binding of trans-
[tetrachloridobis(1H-indazole)ruthenate(III)] anions to albumin. CZE−UV-vis and 
ultrafiltration−UV-vis measurements could also confirm the results of the spectrofluorimetric 
experiments. A result of clinical relevance is the finding that KP1339 and KP1019 are able to 
compete with BR for its binding site under physiological condition and may affect the 
treatment of patients with elevated bilirubin levels.  
 
Materials and methods 
 
Chemicals 
 
KP1019, KP1339, racemic WF, DG, BR, HSA (as lyophilized powder with fatty acids, 
A1653), NaH2PO4, Na2HPO4 and NaCl were obtained from Sigma-Aldrich in puriss quality. 
Doubly distilled Milli-Q water was used for sample preparations.  
HSA solution was freshly prepared before the experiments and its concentration was 
estimated from its UV absorption: 280 nm(HSA) = 36850 M
−1cm−1 [54]. Solutions of WF, DG 
and BR were prepared prior to the analyses with one equivalent of NaOH and their 
concentrations were calculated on the basis of their UV-vis spectra: 308 nm(WF) = 14475 
M−1cm−1, 327 nm(DG) = 5068 M
−1cm−1, 438 nm(BR) = 37950 M
−1cm−1.  
 
Spectrofluorimetric measurements 
 
Fluorescence spectra were recorded on a Hitachi-F4500 fluorimeter using 5 nm/5 nm slit 
width in 1 cm quartz cell at 25.0 ± 0.1 °C. All solutions were prepared in 20 mM phosphate 
buffer (pH 7.40) containing 150 mM M NaCl and were incubated for 15 min. Samples usually 
contained 1 mM HSA (10 mM HSA in BR displacement experiments) and various HSA-to-
ligand ratios (from 1:0 to 1:20) were used. In the site marker displacement experiments the 
HSA-to-site marker (WF, DG or BR) ratio was 1:1 and the concentration of the Ru(III) 
complexes was varied. Spectra were recorded after 10 min incubations. BR-containing 
samples were kept in the dark. The excitation wavelengths were 295, 310, 335 or 487 nm 
depending on the type of the experiment and the emission was read in the range of 310-650 
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nm (see Table S2 for details). The conditional binding constants were calculated with the 
computer program PSEQUAD [44] and quenching data were for comparison purposes also 
analyzed by Stern-Volmer plots (see SI) [45,46]. 
Three-dimensional spectra were recorded at 210-500 nm excitation and 230-650 nm 
emission wavelengths. 
A correction for self-absorbance was necessary in the quenching experiments because 
fluorescence is significantly absorbed by the Ru(III) complexes. Samples containing BR also 
had to be corrected (for the molar absorption spectra of KP1339 and BR see Fig. S9). The 
correction was carried out according to the equation: 
Fcorrected = Fmeasured × 10
(A(EX) + A(EM)) / 2   [45] 
where Fcorrected and Fmeasured are the corrected and measured fluorescence intensities, 
and A(EX) and A(EM) are the absorptivities at the excitation and emission wavelengths in the 
samples, respectively. The inner filter effect in the case of other titrations was negligible and 
therefore no corrections were applied. 
 
Membrane ultrafiltration−UV-vis measurements 
 
Samples were separated by ultrafiltration through 10 kDa membrane filters (Microcon YM-10 
centrifugal filter unit, Millipore) in low (LMM) and high molecular mass (HMM) fractions 
with the help of a temperature controlled centrifuge (Sanyo, 10000/s, 10 min). The samples 
(0.50 mL) contained 60 mM HSA and the metal complexes (from 10 to 150 mM) in 20 mM 
phosphate buffer (150 mM NaCl; pH 7.40 at 25.0 ± 0.1 °C) and were incubated for 15 min. In 
the site marker displacement experiments the HSA-to-site marker ratio was 1:1 and the 
concentration of the Ru(III) complexes was varied (from 10 to 180 mM). The LMM fraction 
containing the non-bound metal complex was separated from HSA and [HSA‒KP1019] (or 
[HSA‒KP1339]) adducts in the HMM fraction. The LMM fractions were diluted to 1.00 mL 
and the concentration of the non-bound complex was determined by UV-vis 
spectrophotometry and in the case of competition measurements by spectrofluorimetry 
(according to the site marker, see details in Table S2 and Fig. S10). The UV-vis spectra of the 
LMM fractions were compared with the reference spectra of the samples containing KP1019 
or KP1339 without the protein at the concentration equal to that in the ultraﬁltered samples. A 
Hewlett Packard 8452A spectrophotometer was used to record the spectra in the region of 
200‒700 nm at 25 °C and a path length of 1 cm.  
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Stoichiometries and conditional binding constants (log') were then calculated based 
on the equilibrium processes and mass-balance equations for the components (see SI) were 
established with the computer program PSEQUAD [44] from the total and protein-free 
concentration data pairs of the ligands obtained at different protein-to-Ru(III) complex ratios; 
uncertainties in the stability constants are given in parentheses. 
 
CZE measurements 
 
CZE experiments were performed with an HP3D CZE system (Agilent Technologies). For all 
experiments capillaries of 48 cm total length (50 μm ID) were used (BGB Analytik AG). The 
detection was carried out by on-column UV photometric measurement in the range of 200-
330 nm. Injections were performed by applying a pressure of 30 mbar for 5 s, and constant 
voltages of 28 kV were used for phosphate buffer at pH 7.40 as background electrolyte 
(BGE). Prior to the first use, the capillary was flushed at 1 bar with 0.1 M HCl, water, 0.1 M 
NaOH and again with water (10 min each). Before each injection, the capillary was purged for 
2 min both with water and the BGE followed by applying a voltage of 28 kV for 30 s and 
flushed for 1 min with BGE again. The cleaning procedure included purging with 0.1 M HCl, 
water and 0.1 M NaOH (each for 2 min). The CZE data was recorded using the ChemStation 
software (HP, Agilent Technologies).  
Samples containing 100 mM HSA and the ligands (from 25 to 800 mM) in 20 mM 
phosphate buffer (150 mM NaCl; pH 7.40 at 25.0 ± 0.1 °C) were incubated for 40 min prior 
to the measurements. In the WF or DG displacement experiments the HSA-to-site marker 
ratio was 1:1 and the concentration of KP1019 or KP1339 was varied (from 25 to 800 mM). 
The peak height of the non-bound site marker was used in order to obtain its concentration 
employing external calibration.  
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Legends to figures 
 
Chart 1 Structures of the Ru(III) complexes KP1019 = indazolium trans-
[tetrachloridobis(1H-indazole)ruthenate(III)]; KP1339 = sodium trans-[tetrachloridobis(1H-
indazole)ruthenate(III)]; NAMI-A = imidazolium trans-[tetrachlorido(dimethylsulfoxide)(1H-
imidazole)ruthenate(III)] 
 
Fig. 1 Fluorescence emission spectra of HSA (dashed line) and the HSA‒KP1339 system 
(solid lines) (a); changes of the emission intensities at 334 nm plotted against the 
concentration of KP1339 (♦) with the Stern-Volmer plot at 334 nm as inset (b)  {cHSA = 1.0 
mM; cKP1339 = 0-15 mM; EX = 295 nm; t = 25 °C; pH = 7.40 (20 mM phosphate buffer; 150 
mM NaCl); PTM = 700 V; Slits: 5/5 nm}. 
 
Fig. 2 Equilibrium concentration of the bound KP1339 plotted against the ratio of HSA to 
KP1339 calculated from the UV-vis spectra of the ultrafiltered LMM fractions of 
HSA‒KP1339 samples (for two parallel measurements: ■, □) together with the values based 
on the determined binding constants (dashed line) {cHSA = 58 mM; t = 25 °C; pH = 7.40 (20 
mM phosphate buffer; 150 mM NaCl)}.  
 
Fig 3 Molar fluorescence emission spectra of WF, [HSA‒WF] (EX = 310 nm), DG, 
[HSA‒DG] (EX = 335 nm) and [HSA‒BR] (EX = 487 nm) {t = 25 °C; pH = 7.40 (20 mM 
phosphate buffer; 150 mM NaCl); PTM = 700 V; Slits: 5/5 nm}. 
 
Fig. 4 Fluorescence emission spectra obtained by the titration of HSA‒WF (1:1) with KP1339 
{cHSA = cWF = 1.0 mM; cKP1339 = 0-18 mM; EX = 310 nm; t = 25 °C; pH = 7.40 (20 mM 
phosphate buffer; 150 mM NaCl); PTM = 700 V; Slits: 5/5 nm}. The inset shows the fitting of 
the intensities at 390 nm between the measured (■) and the calculated values (solid grey line) 
at various KP1339 concentrations.  
 
Fig. 5 Changes of the emission intensities at 500 nm plotted against the concentration of 
KP1019 (♦) and KP1339 (◊) obtained by the titration of HSA‒DG (1:1) with the Ru(III) 
complexes {cHSA = cDG =  1.0mM; EX = 335 nm; t = 25 °C; pH = 7.40 (20 mM phosphate 
buffer; 150 mM NaCl); PTM = 700 V; Slits: 5/5 nm}.  
17 
 
 
Fig. 6 The non-bound WF detected by CZE depicted against the ratio of WF to KP1019 (○) or 
KP1339 (●) in the HSA‒WF‒Ru(III) complex systems {cHSA = cWF =  100 mM; t = 37 °C; pH 
= 7.40 (20 mM phosphate buffer; 150 mM NaCl);  = 310 nm}. 
 
Fig. 7 Changes of the emission intensities at 530 nm plotted against the concentration of 
KP1339 obtained by two parallel titrations of HSA‒BR (1:1) with KP1339 (■, □) together 
with the concentration distribution curves calculated for the system{cHSA = cBR = 10 mM; EX 
= 487 nm; t = 25 °C; pH = 7.40 (20 mM phosphate buffer; 150 mM NaCl); PTM = 700 V; 
Slits: 5/5 nm}.  
 
Fig. 8 Molar fractions of the bound and non-bound Ru(III) complexes in a hypothetical 
HSA‒BR‒KP1339 system at various BR concentrations when cHSA = cKP1339 = 630 mM and 
occupation of only one binding site is presumed {[HSA‒KP1339]: grey; non-bound KP1339: 
black}. 
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Table 1 
Conditional binding constants (logK’) and KD of the [HSA‒Ru(III) complexes] calculated 
from the spectrofluorimetric and ultrafiltration‒UV-vis measurements.a  
 KP1339 KP1019 
Quenching b   
logK’(PSEQUAD) 4.69(6) 5.66(6) 
KD (PSEQUAD) 20.4 mM 2.2 mM 
logK’(Stern-Volmer) 4.66(6); (4.92(2)) 
e - 
KD (Stern-Volmer) 21.9 µM; (12.0 mM) 
e 
- 
Site marker displacement c   
logK’(WF) 5.71(8) 5.83(10) 
logK’(DG) 5.32(13) 5.81(19) 
logK’(BR) 6.01(2) 6.25(6) 
Ultrafiltration‒UV-vis d   
logK’1 4.97(11) 4.7(2) 
logK’2 4.67(5) 4.6(2) 
a Standard deviations in parenthesis. 
b Determined by spectrofluorimetry; {cHSA = 1 mM; t = 25
 °C; pH = 7.40 (20 mM 
phosphate buffer, 150 mM NaCl)}. 
c Determined by spectrofluorimetry; {cHSA = csite marker = 1 mM; t = 25
 °C; pH = 7.40 (20 
mM phosphate 150 mM NaCl)}; For the logK’ values of the HSA‒site marker complexes 
see Table S1. 
d Determined by ultrafiltration‒UV-vis; {cHSA = 60 mM; t = 25
 °C; pH = 7.40 (20 mM 
phosphate buffer, 150 mM NaCl)}. 
e Values in the brackets give the result without applying self-absorbance correction. 
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